CVM

CEL-SCI Corporation (CEL-SCI) - 10-K Summary

Business Context and Reporting Period

Period: Fiscal year ended September 30, 2001.
Business: CEL-SCI is a biotechnology company focused on the research and development of immunotherapies. Its primary product candidate is MULTIKINE, a cytokine cocktail designed to boost immune responses in cancer and HIV patients. The company is also developing the L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology for vaccines against diseases such as malaria, herpes, and cancer.
Status: The company is in the pre-commercial clinical trial phase with no product sales revenue. Operations are funded through equity sales, debt financing, and investment income.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by approximately 27% to $10.7 million, driven primarily by a 50% increase in R&D expenses ($7.76M vs $5.19M) due to manufacturing costs for MULTIKINE and clinical trial validation.
• Liquidity Decline: Cash and cash equivalents dropped significantly from $6.9 million in 2000 to $1.8 million in 2001. Working capital decreased from $11.7 million to $2.8 million.
• Compensation Charges: General and Administrative expenses included $593,472 in charges for repriced employee stock options and $316,501 for options/stock granted to non-employees.
• Investment Portfolio: The company reduced its investment securities from $3.76 million to $0.59 million, likely to fund operations.

Outlook, Risks, and Unusual Items

• Capital Requirements: Management expects significant spending on R&D and clinical trials in fiscal 2002. The company relies on an equity line of credit with Paul Revere Capital Partners (up to $10M) and recent convertible note agreements ($800,000) to fund operations.
• Clinical Progress:
  • MULTIKINE: Phase I trials for HIV-infected women with HPV-induced cervical dysplasia showed 75% of patients had no evidence of dysplasia on biopsy. The company plans to prioritize this indication and meet with the FDA in 2002.
  • L.E.A.P.S.: Preclinical studies are ongoing for malaria, herpes, and cancer vaccines.
• Debt and Financing Risks:
  • Issued a $1.159 million promissory note to Cambrex Bio Sciences for manufacturing costs, due January 2003.
  • Convertible notes issued in December 2001 carry a 7% interest rate and contain restrictive covenants, including limitations on dividends and future equity sales.
  • Failure to raise additional capital could force the company to reduce discretionary expenditures, delaying product development.
• Regulatory Risk: No assurance exists that clinical trials will be accepted by the FDA or that products will ever receive marketing approval. Commercialization is likely years away.

Investor Verification Checklist

• Cash Runway: Verify if the $1.78M cash balance and the $10M equity line are sufficient to fund the planned 2002 clinical trials without immediate dilution.
• Convertible Note Terms: Review the specific redemption triggers (130% penalty) and anti-dilution provisions in the December 2001 convertible note agreement.
• Stock Option Dilution: Assess the impact of the 1.3 million options repriced in July 2001 and the 960,000 Series F warrants issued in December 2001 on future share count.
• Manufacturing Dependency: Confirm the status of the relationship with Cambrex Bio Sciences, the owner of the manufacturing facility, given the outstanding promissory note.
• FDA Engagement: Monitor the outcome of the planned 2002 meetings with the FDA regarding the cervical dysplasia trial design.